IXICO PLC (AIM:IXI, OTC:PHYOF), a neuroscience imaging company, has secured a new contract with a US-based client for a phase II clinical trial in Huntington's Disease.
The agreement, valued at over £500,000, will span around two-and-a-half years.
CEO Bram Goorden said: "This contract further demonstrates IXICO's expertise in supporting neurodegenerative disease trials, reinforcing our role as a trusted partner for sponsors.
"Through this work we are proud to continue our support of the Huntington's Disease community, in collaboration with our sponsor, working towards a breakthrough in this challenging field."
A rare hereditary neurodegenerative disorder, Huntington's Disease impairs motor skills, cognitive function, and emotional well-being.